3rd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics

The future of Antibody Drug Conjugates (ADC) continues to evolve driving the need for a platform to discuss the latest in ADC development. Vonlanthen Group of Companies is pleased to help continue that conversation with the 3rd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics in Barcelona, Spain on 17th - 18th May, 2018.

This Summit will provide presentations that will give an up-to-date look at the challenges, lessons learned, and best practices for ADC from development to therapeutics. By coupling these case studies with networking opportunities, attendees will receive a well-rounded view of the current state of ADCs. This will result in attendees leaving with the knowledge of practical applications that can be used within their own business strategies.

We are very honoured to invite you to be a part of this elite event. We look forward to seeing you in Barcelona!

Key Practical Learning Points of the Summit:

  • An expert look at ADCs to help with ADC adoption within your business
  • The latest developments, technologies, and methods in design and creation of ADCs
  • Strategies and lessons learned to expedite preclinical development and aid in the successful translation into clinic
  • Ways to enhance the ADC therapeutic risk-benefit ratio

Who Should Attend:

Chief Executives, Vice Presidents, Directors, Department Heads, Leaders, Managers, Clinical Development Experts, and Scientists specialising in:

  • Antibody& Biologics Discovery/Development
  • Manufacturing/CMC
  • Protein Engineering
  • Molecular Biology
  • Medicinal Chemistry
  • Antibody Drug Conjugates (ADC)
  • Bioconjugates
  • Immunoconjugates
  • Monoclonal Antibodies (mAbs)
  • Maytansine
  • Duocarmycin
  • PBD-dimers
  • ?-amanitin
  • Topoisomerase inhibitors
  • Marine-Based Cytotoxins
  • Small-Molecule Drug Conjugates
  • Peptide-Drug Conjugates
  • Nanoparticles/Nanobodies
  • Diabodies/Minibodies
  • PKPD
  • ADME
  • Toxicology
  • Analytical & Formulation
  • Bioanalysis
  • Cancer
  • Oncology
  • Hematology
  • Antibody-Based Therapeutics
  • Biotherapeutics
  • Immunotherapeutics
  • Chemotherapeutics